ClinicalTrials.gg
RecruitingNCT07362875DeQoDE-DMUpdated Jan 23, 2026

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

An observational study in Myotonic Dystrophy, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Wake Forest University Health Sciences · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
18th of 21
75 · median 125
Started
2025
with 5 others
Observational
21 of 43
15 open now
Primary completion
2029-05
later than 16 of 26 live
Registered
37th of 43
by date
Lead sponsor
2 of 43
Wake Forest University Health Sciences

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 6 that started in 2025, is one of 21 observational ones, reaches primary completion later than 16 of the 26 other live ones, and was the 37th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.

Read the detailed description

Past and current clinical trials in DM1 have relied on muscle biopsies to evaluate pathology and measure drug activity. However, this method is invasive and inefficient for long-term monitoring. What is lacking are non-invasive imaging biomarkers capable of providing comparable data, which would enhance trial planning, accelerating drug development while reducing morbidity and costs. Non-invasive muscle imaging, particularly through Quantitative Magnetic Resonance Imaging (qMRI), is essential to better understand how DM affects muscle structure. Moreover, the relationships between Magnetic Resonance Imaging (MRI) measures, disease severity, and Ribonucleic Acid (RNA) splicing outcomes from muscle tissues in the same DM patients are not yet known. As MRI has been relatively unstudied in DM, there needs to be a comprehensive baseline characterization of muscle structure and its relationship to clinical endpoints and RNA-associated disease processes. This will help evaluate the potential of qMRI as a biomarker of disease severity in DM.

03

Conditions studied

  • Myotonic Dystrophy

Keywords

  • dystrophia myotonica
  • muscular dystrophy
  • skeletal myopathy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The selection criteria will minimize the heterogeneity effects and mirror DM subjects likely to be selected for clinical trials, who are typically mildly to moderately affected. Subjects will be recruited from the Wake Forest Neuromuscular Clinic and nearby medical centers (Duke University, UNC Chapel Hill, and Atrium Health in Charlotte).

Since DM2 is rarer than DM1 and patients live across the country, additional recruitment efforts will target DM2 subjects through the Myotonic Dystrophy Foundation Family Registry (MDFR).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

DM subjects

  • Age 18 - 65 years
  • Diagnosis of DM1 or DM2 by clinical or genetic criteria. If DM1 or DM2 was diagnosed by clinical criteria, a first-degree relative must have genetic testing confirmation and sign a genetic consent form to release their genetic information
  • Clinically affected, as defined by muscle weakness or myotonia
  • Ambulate independently (a walker is not permitted)
  • Able to provide for participation in the study

Control subjects

  • Age 18 - 65 years old
  • Healthy as defined by no significant medical or neurological conditions
  • Able to provide informed consent for participation in the study

Exclusion criteria

Exclusion Criteria:

  • Cardiac pacemaker, defibrillator, metal implants, or other for MRI
  • Use of anabolic or catabolic agents within one year of entry
  • History of lumbar spine or leg surgery, lumbar radiculopathy, or peripheral neuropathy
  • > 35 because obesity compromises positioning on the MR scanner
  • Pregnancy
  • For muscle , history of bleeding disorders or on anticoagulation. Subjects taking nonsteroidal anti- inflammatory agents will be asked to discontinue these medications 7 days prior to muscle biopsy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • DM subjects

    1. Age 18 - 65 years 2. Diagnosis of DM1 or DM2 by clinical or genetic criteria. If DM1 or DM2 was diagnosed by clinical criteria, a first-degree relative must have genetic testing confirmation and sign a genetic consent form to release their genetic information. 3. Clinically affected, as defined by muscle weakness or myotonia 4. Ambulate independently (a walker is not permitted) 5. Able to provide informed consent for participation in the study

  • Control subjects

    1. Age 18 - 65 years old 2. Healthy as defined by no significant medical or neurological conditions 3. Able to provide informed consent for participation in the study

06

What researchers measure

Primary outcomes

  1. Contractile muscle volume (CMV, cm3)

    Contractile muscle volume (CMV, cm3) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments

    Time frame: Baseline

  2. Muscle fat fraction (MFF, %)

    Muscle fat fraction (MFF, %) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments

    Time frame: Baseline

Secondary outcomes

  1. Average measures of Manual muscle testing (MMT)

    MMT will be performed in 7 different muscle groups (hip flexors, hip abductors, knee flexors, knee extensors, ankle dorsiflexors, plantar flexors, and neck flexor) in standardized positions. Each group will be scored using a 13-point modified Medical Research Council (MRC) scale and standardized positions. Where 0 is paralysis, 1 is a flicker/trace contraction, 2 is movement with gravity eliminated, 3 is movement against gravity, 4 is movement against some resistance, and 5 is normal strength against full resistance - higher scores denoting stronger muscles

    Time frame: Baseline

  2. Average measures of Quantitative Muscle Testing (QMT)

    QMT of the leg muscles (hip flexors, hip abductors, knee extensors, knee flexors, ankle dorsiflexors, and plantar flexors) will be performed using a hand-held dynamometer in standardized positions. During the measurement, the subject will be instructed to increase to maximum exertion over a few seconds without jerking, and to maintain this effort until the evaluator give the command to relax (3-5 seconds). The clinical evaluator will hold the dynamometer stable, and the subject will be asked to push as hard as possible against the applicator, but with a slow build-up of force. The subject will perform each push three times with up to a 30-second pause between each trial. The average and highest scores obtained will be used for analysis.

    Time frame: Baseline

  3. Average measures of grip strength (pounds or kilograms)

    Use Jamar handgrip dynamometer to test handgrip strength. We will test each subject three trials, starting with a dominant hand first, then a non-dominant hand. An average score in each hand will be used for analysis. Higher scores denote stronger grip strength - It works by squeezing the device to its maximum, revealing strength in pounds or kilograms (up to 200 lbs/90 kg)

    Time frame: Baseline

  4. Average measures of pinch strength

    The subject will perform quantitative pinch strength testing with a pinch gauge - higher numbers denote stronger pinch strength - Normal range: 10-20 pounds of force

    Time frame: Baseline

  5. The 6-minute walk test (6MWT) times

    walking ability in muscular dystrophies, the 6MWT probably offers the best combination of reliability, sensitivity, clinical significance, and feasibility for clinical trials. The procedures will be performed in a standardized manner following the guidelines of the American Thoracic Society. Lower times denote faster walks

    Time frame: Baseline

  6. gait speed times

    Subjects will be instructed to walk at maximum speed in a long corridor with an even surface over 10 meters with a still-standing start and a "flying" finish. The subjects will be instructed to continue walking to a target 2.5 meters beyond the mark at 4 and 10 meters, where the clinical evaluator stands. The time will be measured with the stopwatch and is started on the word "Go" ("Ready-Set-Go") until subject reaches a 4 and 10-meter mark. Lower times denotes faster speeds

    Time frame: Baseline

  7. step test amount

    The subject will stand unsupported 5 cm in front of a block (maximum height 10 cm) and make as many "full steps" as possible during 15-second period. One step comprises placing one foot fully up onto and then down off the block. Both legs will be tested, one foot at a time. The subject will allow some practice steps and then one test attempt per leg. If balance is lost during the trial, the completed steps will be reported. Clinical Evaluator will kneel by the block and holds it to ensure it remains steady during the test. higher scores denotes better balance and strength

    Time frame: Baseline

  8. sit-to-stand test amount

    The test will be administered using a standard chair with a seat height of 17 inches (43.2 cm) and rubber tips on the legs. The test begins with the subject seated in the middle of the chair, back straight, feet approximately shoulder-width apart and place on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance when standing. Arms are crossed and held against the chest. At the signal "go," the subject will rise to a full stand and then return to the initial seated position. The subjects will be encouraged to complete as many full stands as possible within a 30-second time limit. The score will be the total number of stands executed correctly. Incorrectly executed stands will not be counted - higher scores denotes better balance and strength

    Time frame: Baseline

  9. Short Physical Performance Battery (SPPB) Scores

    The physical performance will be assessed using the expanded SPPB commonly used in research. The SPPB measures physical function using three components: 4-meter natural gait speed, time to complete five chair rises, and standing balance with a narrow base of support. Each component is scored on a 0-4 scale and summed for an overall score range of 0-12. The SPPB is a reliable and validated measure of physical function in the older population that can be collected safely and easily at clinic, home, or hospital setting. Overall scores and components of SPPB are highly predictive of clinical outcomes, including disability, hospitalization, and death. The SPPB is also sensitive to change over time and responsive to exercise training. A clinically meaningful but small change in SPPB score is 0.5 units, and a substantial change is 1.0 units

    Time frame: Baseline

  10. Nine-Hole Peg Test (9HPT) times

    The test will evaluate upper extremity function, specifically fine dexterity, and coordination. test each subject once, starting with a dominant hand first, then a non-dominant hand. One practice trial (per hand) should be provided before timing the test. The subjects will be instructed to pick up the pegs one at a time using one hand only and put them into the holes one at a time and return each of them to the container. Lower times denotes higher dexterity and coordination

    Time frame: Baseline

  11. Time Up and Go (TUG) times

    TUG is used to evaluate various aspects of dynamic stability related with falls. A TUG time \> 14 seconds is associated with falls in DM1. The TUG includes rising from a chair, walking 3 meters, turning, walking back, and sitting down. The TUG shows good test-retest reliability (ICC \> 0.8) in individuals with DM1 - scores under 10 seconds are normal, under 20 seconds indicate good mobility, while over 30 seconds suggests significant impairment, requiring assistance and indicating a high fall risk, with 14+ seconds signaling increased risk.

    Time frame: Baseline

  12. DM1-Activity and Participation Scale (DM1-Activ) Scores

    The DM1-Activ is a 25-item instrument, designed to assess activity limitations in individuals with DM1. It has been validated as a disease-specific PRO measure for assessing activity limitations in DM1 with good internal consistency and constructive validity. It captures the impact of DM1 on daily activities and physical function, making it a valuable tool for clinical trials and disease monitoring - using response options from "impossible" to "without difficulty"

    Time frame: Baseline

  13. Patient-Reported Outcomes Measurement Information System (PROMIS-10) Scores

    assessing global health (physical and mental) and social well-being. It evaluates health symptoms and quality of life sub-domains such as pain, fatigue, physical activity, and global health (GH). PROMIS is well-validated with chronic neurological conditions, demonstrating strong internal consistency and cross-sectional validity. use PROMIS-10, a 10-item questionnaire, assessing multiple health domains. This tool provides less ceiling effect and has been accepted as a key outcome in the NINDS Common Data Elements. The raw responses (1-5 scale) are converted to these T-scores, allowing for interpretation like scores above 60 being moderately worse than average and below 40 being significantly better.

    Time frame: Baseline

  14. Brief Pain Inventory (BPI) Scores

    The short form BPI is designed to measure the interference pain has with patient daily activities. These scales were selected based on their validity, simplicity, ability to detect change in pain with treatment, patient relevance, reliability, test-retest scores, and their previous use in pain studies of the myotonic dystrophy population - uses 0-10 scales to quantify pain severity (worst, least, average, current) and interference with daily life (mood, activity, sleep, etc.), with higher numbers indicating worse pain or interference

    Time frame: Baseline

  15. Checklist Individual Strength (CIS-fatigue) Scores

    The level of fatigue will be assessed using the CIS 'fatigue severity' subscale. It measures the experience of fatigue-associated problems during the past 2 weeks. The CIS-fatigue severity subscale contains eight items (items 1, 4, 6, 9, 12, 14, 16, 20) scored on a 7-point Likert scale. Scores can range between 8 and 56 with higher scores indicating higher levels of fatigue and scores of \> 35 or more are indicated severe fatigue

    Time frame: Baseline

  16. Muscular Impairment Rating Scale (MIRS) Scores

    MIRS is a quick, simple, and reliable scale to evaluate muscle impairment in DM1. It has been validated with motor activities and functional status index questionnaire. It is a five-ordinal scale with the definition of the grades as follows: 1=no impairment; 2=minimal signs, as ptosis and nasality, no distal weakness except long finger flexor weakness; 3=distal weakness, no proximal weakness except in elbow extensors; 4=mild to moderate proximal weakness; and 5=severe proximal weakness. This will be tested for DM1 subjects only. The MIRS is useful to monitor severity stages of disease progression and to identify homogeneous groups of patients for trials

    Time frame: Baseline

  17. presence of edema-liked changes

    MRI Short Tau Inversion Recovery (STIR) sequence data will be evaluated for edema-like changes by assessing the presence or absence of signal hyperintensity in each muscle by a consultant radiologist - STIR (Short Tau Inversion Recovery) sequence is a special MRI technique that suppresses (blacks out) the signal from fat, making it excellent for highlighting fluid-filled tissues like edema (swelling), inflammation, tumors, and stress fractures, especially in bone marrow and soft tissues, because it makes these pathologies appear bright against the dark background of fat.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
May 15, 2025
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362875
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
May 15, 2025
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jan 23, 2026

Study contacts

Elizabeth (Gracie) G Hilber
Contact
Elizabeth.Hilber@Advocatehealth.org
336-716-4163
Constance Linville
Contact
Martha.Linville@advocatehealth.org
704-355-2000
Araya Puwanant, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion